Cue Biopharma (CUE) Total Current Liabilities (2017 - 2025)

Cue Biopharma has disclosed Total Current Liabilities across 9 years of filings, most recently posting $13.5 million for Q4 2025.

• Total Current Liabilities for Q4 2025 came in at $13.5 million, down 1.42% year-over-year; the trailing twelve-month figure through Dec 2025 was $13.5 million (down 1.42% YoY), and the FY2025 annual result was $13.5 million, down 1.42% from the prior year.
• Total Current Liabilities came in at $13.5 million for Q4 2025 at Cue Biopharma, down from $15.5 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $19.3 million in Q2 2025 to a low of $8.3 million in Q2 2022.
• The 5-year median for Total Current Liabilities is $15.5 million (2025), against an average of $14.8 million.
• Across the five-year window, Total Current Liabilities plunged 50.08% in 2022 and soared 95.93% in 2023, its largest moves.
• Cue Biopharma's Total Current Liabilities stood at $12.8 million in 2021, then declined by 9.69% to $11.5 million in 2022, then jumped by 47.91% to $17.1 million in 2023, then fell by 19.86% to $13.7 million in 2024, then fell by 1.42% to $13.5 million in 2025.
• The last three Total Current Liabilities figures came in at $13.5 million (Q4 2025), $15.5 million (Q3 2025), and $19.3 million (Q2 2025), per Business Quant data.